Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:57:32.912Z.
Calculation as of: 2026-10-06T15:57:32.912Z.
Quote observation: 2026-10-06T15:49:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fae3dac89f6aae568c3e1e6131ec6a0b9ed594063ed7dd46d2bf25dadf8b5230
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
OKYO Pharma Limited
Market Cap
$56.98M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.98M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.55M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.66M | N/A |
| Spectral AI, Inc. (MDAI)vs › | $54.90M | N/A |
| Aldeyra The (ALDX)vs › | $54.48M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $59.37M | N/A |
| ImageneBio Inc (IMA)vs › | $53.80M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.18M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
